ACADIA Pharmaceuticals (NASDAQ:ACAD) Earns Hold Rating from Analysts at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft began coverage on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) in a research report report published on Tuesday, Marketbeat Ratings reports. The firm issued a hold rating and a $22.00 price target on the biopharmaceutical company’s stock.

ACAD has been the topic of a number of other research reports. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. StockNews.com cut ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Finally, Guggenheim lowered ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $23.00 to $20.00 in a research report on Friday, January 3rd. Eight research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.00.

ACADIA Pharmaceuticals Stock Performance

ACAD stock opened at $18.49 on Tuesday. The firm has a market cap of $3.08 billion, a P/E ratio of 23.71 and a beta of 0.37. The firm’s fifty day moving average is $17.85 and its 200 day moving average is $16.64. ACADIA Pharmaceuticals has a 52 week low of $14.15 and a 52 week high of $26.78.

Insider Transactions at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, CFO Mark C. Schneyer sold 10,259 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total transaction of $172,453.79. Following the completion of the sale, the chief financial officer now directly owns 53,302 shares of the company’s stock, valued at approximately $896,006.62. This represents a 16.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider James Kihara sold 4,073 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total transaction of $68,467.13. Following the sale, the insider now directly owns 19,863 shares of the company’s stock, valued at $333,897.03. The trade was a 17.02 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 24,661 shares of company stock worth $414,551. Insiders own 28.30% of the company’s stock.

Institutional Trading of ACADIA Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Values First Advisors Inc. purchased a new stake in shares of ACADIA Pharmaceuticals in the 3rd quarter valued at $27,000. R Squared Ltd purchased a new stake in ACADIA Pharmaceuticals in the fourth quarter valued at $47,000. Quest Partners LLC grew its position in ACADIA Pharmaceuticals by 42.3% during the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 1,047 shares during the period. KBC Group NV raised its stake in shares of ACADIA Pharmaceuticals by 67.0% during the 4th quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 2,044 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of ACADIA Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 1,066 shares during the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.